ArticleProbiotics and antimicrobial proteins2026
Characterization and Biofungicide Potential of a Novel Antifungal defensin, K4CBP6, from Solanum lycopersicum L.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The global rise in resistance to chemical fungicides and their strict regulation by the EU, has created an urgent need for alternative antifungal strategies in agriculture. Plant defensins represent promising alternatives owing to their broad-spectrum antifungal activity, structural stability, and low toxicity to mammalian cells and plants. In this study, we identified and characterized a novel antifungal defensin, K4CBP6, from Solanum lycopersicum L., along with its γ-core peptide derivatives, K4CBP6γ1 and K4CBP6γ2, as potential biofungicide agents. Protein database mining revealed a widespread distribution of K4CBP6 homologs within the Solanaceae family. Recombinant K4CBP6 (rK4CBP6) was successfully produced using a Komagataella phaffii-based expression system, while K4CBP6γ1 and K4CBP6γ2 were chemically synthesized. Structural analyses via electrospray ionization mass spectrometry and electronic circular dichroism spectroscopy confirmed a cysteine-stabilized α-helix β-strand folded structure for rK4CBP6. In vitro susceptibility assays demonstrated that both rK4CBP6 and K4CBP6γ2 exhibited antifungal activity against major tomato pathogens, Botrytis cinerea, Cladosporium herbarum, and Fusarium oxysporum with minimum inhibitory concentrations ranging from 12.5 to 25 µg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.